Coussons, P.J., Baig, S., Fanutti, C. and Grant, R. (2005) Novel tissue remodelling roles for human recombinant erythropoietin. Biochemical Society Transactions, 33(5), pp. 1129-1130. ISSN (print) 0300-5127Full text not available from this archive.
rHuEPO (recombinant human erythropoietin) is a haemopoietic growth factor and a primary regulator of erythropoiesis that is used for the treatment of chronic anaemia associated with RA (rheumatoid arthritis). Erythropoietin also appears to modulate a broad array of cellular processes, including progenitor stem-cell development, cellular integrity, angiogenesis and oxidative damage. These diverse activities suggest the exciting possibility of multiple roles for rHuEPO therapy in a variety of disorders other than RA, including cerebral ischaemia, myocardial infarction, chronic congestive heart failure and cancer. Thus it appears that rHuEPO may be a pleiotropic agent, capable of influencing tissue remodelling independently of its established erythropoietic role. Whereas these effects may be largely beneficial, dose-related side effects could have implications for the safe therapeutic use of rHuEPO and its illegal use as a performance-enhancing agent in endurance sports.
|Research Area:||Pre-clinical and human biological sciences|
|Faculty, School or Research Centre:||Faculty of Science (until 2011) > School of Life Sciences|
|Depositing User:||Susan Miles|
|Date Deposited:||04 Nov 2011 09:36|
|Last Modified:||04 Nov 2011 09:36|
Actions (Repository Editors)
|Item Control Page|